Dehydration

DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

Retrieved on: 
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Prostate, Congress, Patient, Sustainable development, Lung cancer, Index (publishing), Immunoglobulin G, Safety, Head, Adult, Dehydration, Causality, Breast, Breast cancer, Chills, Bendell, Progression-free survival, Interstitial lung disease, Plexxikon, Research, Bachelor of Pharmacy, Oncology, Thought, Bladder cancer, DXD, CRO, Veni, vidi, vici, Fatigue, Endometrial cancer, ILD, MD, ADC, Anemia, Cancer, Squamous cell carcinoma, Lymphocyte, Laboratory, Vomiting, Appetite, European Society for Medical Oncology, Death, Cardiovascular disease, Senior, MTD, Sarah Cannon Research Institute, Melanoma, Quality of life, Technology, Oncotarget, Doctor of Philosophy, PRS, RDE, Cleavage, Nausea, Daiichi Sankyo, Diarrhea, Fever, Lung, Pharmaceutical industry, Medical imaging, Fine chemical, Silviculture, B7-H3, the DS-7300 Study, DS-7300, Daiichi Sankyo in Oncology, B7-H3, THE DS-7300 STUDY, DS-7300, DAIICHI SANKYO IN ONCOLOGY

New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.

Key Points: 
  • New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.
  • DS-7300 was tolerated across all dose levels (0.8 mg/kg -16.0 mg/kg) with no dose-limiting toxicities observed in 70 patients enrolled.
  • Stable disease has been reported in an additional 32 patients including 24 patients who are still being treated with various doses of DS-7300 as of data cut-off of July 21, 2021.
  • Patients enrolled in the dose escalation study received a median of four prior lines of therapy (range, 1-10).

2021 Report on Radiation Toxicity Drugs In Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 16, 2021
Health, Biotechnology, Bruise, Discovery, Confusion, R, Acute radiation syndrome, Nose, Radiation Sickness, Tissue, File, Chronic radiation syndrome, ROA, Decision-making, Bleeding, Fatigue, Dehydration, Syndrome, Therapy, Medicine, Mouth, Mall of America, Syncope, Toxicology, Diarrhea, Radiation, Company, History, Time, SEC, Toxicity, Research, Rectum, News, Medical device, Medical imaging, Pharmaceutical industry

This report provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Key Points: 
  • This report provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.
  • The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

Research Led by FDB Pharmacists and Health System Clinicians Further Shatters Age-Old Iodine Allergy Myth

Retrieved on: 
Wednesday, September 15, 2021
Precision medicine, Patient safety, Anaphylaxis, Food, Prescription, SAN, American Academy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDB, FDA, Steroid, Decision-making, Pharmacist, Shellfish, Seafood, Pharmacy, Mayo Clinic, Doctor of Pharmacy, MHK, Patient, Degenerative disease, Allergy, Thyroid, Society, MCG, Pharmacy management system, BCPS, YouTube, LinkedIn, Trauma, Neoplasm, Safety, Dehydration, Physician, Iodine, Solution, MD, Hearst, American Journal of Health-System Pharmacy, Asthma, Amiodarone, First Databank, Twitter, Blood, American Journal, American Academy of Allergy, Asthma, and Immunology, Radiology, Povidone-iodine, Hospital, Rash, Face, Agent handling, Research, Cancer, Tongue, American College, Sudarshan K. Aggarwal, Pharmaceutical industry, Medical imaging

The findings were recently published in the American Journal of Health-System Pharmacy , a peer-reviewed journal of the American Society of Health-System Pharmacists.

Key Points: 
  • The findings were recently published in the American Journal of Health-System Pharmacy , a peer-reviewed journal of the American Society of Health-System Pharmacists.
  • Sixty-six percent to 89% of physicians routinely ask patients prior to an imaging test if they have an iodine allergy or an allergy to shellfish or other seafood that may contain iodine.
  • FDB (First Databank) is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions.
  • The Hearst Health network includes FDB (First Databank), Zynx Health , MCG , Homecare Homebase and MHK (formerly MedHOK).

Vector Laboratories Completes $124 Million Buyout; Initiates Acquisition Strategy; Appoints Former 10x Genomics and Maravai LifeSciences Exec as CEO; Launches VectaMount Express

Retrieved on: 
Tuesday, September 7, 2021

Previously, she served as VP of Marketing at 10x Genomics, having led marketing during the company's hyper-growth phase.

Key Points: 
  • Previously, she served as VP of Marketing at 10x Genomics, having led marketing during the company's hyper-growth phase.
  • "For over 40 years, Vector Laboratories' products have been trusted by disease and therapeutic researchers to accelerate their lab processes and improve productivity.
  • As a newly private company, Vector Laboratories today also launched VectaMount Express, a novel mounting medium for immunohistochemistry applications.
  • Maravai LifeSciences acquired the company in 2016, recognizing that Vector Laboratories has "exceptional products, a history of success and outstanding growth possibilities."

Aflac Launches Awareness Campaign During National Sickle Cell Awareness Month

Retrieved on: 
Wednesday, September 1, 2021
Children's Miracle Network Hospitals, Aflac, Program, Internal medicine, Research, MSM, Hospital, Awareness, Health, Annals of Internal Medicine, Color, Hematology, African Americans, School, Fortune, Sickle Cell Disease Association of America, Pain, EDT, Policy, Sickle cell trait, Degenerative disease, South by Southwest, Morehouse School of Medicine, Health equity, Bloomberg, Sickle cell disease, Commission, Insurance, Disease, St. Louis Fed Financial Stress Index, World, Public policy, HBCU, Faculty, Electronics, Association, Face, Lists of diseases, Cancer, Physician, AFL, Consumer Electronics Show, NYSE, Multimedia, Temperature, Education, Patient, Invention, Facebook, Dehydration, SCD, Parent, Pharmaceutical industry, Health insurance

Beginning in early 2022, Aflac will expand its successful My Special Aflac Duck program to children with sickle cell disease (SCD).

Key Points: 
  • Beginning in early 2022, Aflac will expand its successful My Special Aflac Duck program to children with sickle cell disease (SCD).
  • Since 1995, Aflac has contributed more than $155 million to the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta , including the sickle cell disease program.
  • The integrated campaign, #AflacSickleCellSense, includes real stories from people facing sickle cell disease and celebrities with family members who have been impacted by the disease.
  • I applaud Aflac for their decision to provide their comforting My Special Aflac Duck to help ease the pain that children with sickle cell disease often endure.

T-Mobile Accelerator Kicks Off Fall Program Fueling 5G Innovation in Wellness Tech

Retrieved on: 
Tuesday, August 31, 2021
Consumer Electronics, Technology, Mobile, Wireless, Telecommunications, Networks, Internet, LTE, Golf, T-Mobile, Quality of life, Program, UN, Metro, Smoking, XR, Growth, University, Emerging technologies, Communication, Peachtree Corners, Georgia, Hearing, Artificial intelligence, TMUS, Android, Decision-making, AT, Health, IOS, Lead, EVP, Injury, Smartglasses, NASDAQ, Risk, Verizon Communications, Falling, Acceleration, AT&T, Assistive Technology for Deaf and Hard of Hearing, Hard, Georgia Tech, Dehydration, Ministry of Education (Malaysia), Technology, Animal, Television, Mobile phone, Video game

T-Mobile (NASDAQ: TMUS) has kicked off its Fall 2021 T-Mobile Accelerator Wellness Technology Program.

Key Points: 
  • T-Mobile (NASDAQ: TMUS) has kicked off its Fall 2021 T-Mobile Accelerator Wellness Technology Program.
  • Participants in the T-Mobile Accelerator Fall 2021 program include:
    formsense (San Diego, CA).
  • With its supercharged 5G network as the foundation, T-Mobile is fueling 5G innovation and building the 5G ecosystem with a number of initiatives.
  • In addition, it operates the T-Mobile Ventures investment fund and it is a co-founder of the 5G Open Innovation Lab .

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

Retrieved on: 
Thursday, August 26, 2021
Health, FDA, General Health, Clinical Trials, Research, Science, Pharmaceutical, Population, Astellas Pharma, Drug development, Death, Pain, CIC, Incidence, Trial of the century, AbbVie, Constipation, Safety, Bloating, Food, Ironwood Pharmaceuticals, Time, Abdominal pain, Irritable bowel syndrome, IQVIA, Nationwide, Medication, NASDAQ, Mortality, Risk, Adult, Patient, Diarrhea, FDA, IBS-C, GC, Dehydration, AstraZeneca, FC, GC-C, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Dietary supplement, Pharmaceutical industry, Phosphorus, Birth control, LINZESS (linaclotide), Ironwood Pharmaceuticals, LINZESS (LINACLOTIDE), IRONWOOD PHARMACEUTICALS

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that has been generated thus far in pediatric studies.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that has been generated thus far in pediatric studies.
  • This label update reflects a significant milestone, and we look forward to continuing to investigate the safety and efficacy of LINZESS for children.
  • LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists.
  • In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC.

AgroFresh Awarded Overall Food Quality Solution of the Year at AgTech Breakthrough Awards

Retrieved on: 
Wednesday, August 25, 2021
Industry, IOT, Food quality, GLOBE, Agtech, Leadership, Nasdaq, Citrus, Solution, Food technology, Automation, Food loss and waste, Ernst & Young Entrepreneur of the Year Award, Robotics, Dehydration, Management control system, Artificial intelligence, Taste, Technology, Data analysis, Agriculture

PHILADELPHIA, Aug. 25, 2021 (GLOBE NEWSWIRE) -- AgroFresh Solutions, Inc. (Nasdaq: AGFS), a global AgTech leader, announced today that it has received the Overall Food Quality Solution of the Year Award at the AgTech Breakthrough Awards .

Key Points: 
  • PHILADELPHIA, Aug. 25, 2021 (GLOBE NEWSWIRE) -- AgroFresh Solutions, Inc. (Nasdaq: AGFS), a global AgTech leader, announced today that it has received the Overall Food Quality Solution of the Year Award at the AgTech Breakthrough Awards .
  • The awards are conducted by AgTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global agricultural and food technology markets.
  • The mission of the annual AgTech Breakthrough Awards program is to conduct the industrys most comprehensive analysis and evaluation of agricultural and food technology markets, including Internet-of-Things (IoT) and Artificial Intelligence (AI) based agricultural technologies, farm management, indoor farming, food quality, data analytics and many more.
  • The AgTech Breakthrough Awards program provides a forum for public recognition around the achievements of AgTech companies and solutions in categories including farm management, indoor farming, automation, IoT and robotics, food quality, analytics and more.

Global Adsorbents Market Forecasts to 2026: Increase in Demand for Oxygen Concentrators - ResearchAndMarkets.com

Retrieved on: 
Monday, August 23, 2021
Other Manufacturing, Manufacturing, Carbon, CAGR, Growth, Mercury, Glass, Adsorption, Alkylation, Petroleum, Chemistry, Sieve analysis, Silica gel, Oil refinery, Region, Dehydration, USD, Oil, Uranium

Molecular Sieves is the fastest-growing type segment in the Adsorbents market.

Key Points: 
  • Molecular Sieves is the fastest-growing type segment in the Adsorbents market.
  • The adsorbents market in APAC is driven by the demand from countries such as China, Japan, and India.
  • Rapid industrialization, mainly in emerging economies such as China and India, has been one of the major factors driving the global adsorbents market.
  • The market in APAC, owing to high demand, is much more dynamic and competitive than that in the western region.

Stay Hydrated in Summer Heat

Retrieved on: 
Monday, August 9, 2021
Environment, Women, Utilities, Men, Other Natural Resources, Energy, General Health, Consumer, Health, Natural Resources, Commonwealth, Environment, Water, Thirst, Headache, History, Fire hydrant, Drinking water, Time, Pennsylvania-American Water Company, Fatigue, Cramp, Xerostomia, Dizziness, Nausea, NYSE, AC, LinkedIn, Dehydration, Safety, American Water, Instagram, Twitter

As the dog days of summer set in and high temperatures are forecasted in the 90s across much of the Commonwealth this week, Pennsylvania American Water reminds customers to stay healthy and hydrated.

Key Points: 
  • As the dog days of summer set in and high temperatures are forecasted in the 90s across much of the Commonwealth this week, Pennsylvania American Water reminds customers to stay healthy and hydrated.
  • Safety is one of our top priorities at Pennsylvania American Water, and dehydration is a serious safety concern for employees and customers alike in this summer heat, said Mike Doran, president, Pennsylvania American Water.
  • We hope these tips will help our customers develop good hydration habits and avoid the dangers of dehydration this summer.
  • For more hydration tips, watch the companys Summer Hydration Index video and follow Pennsylvania American Water on Facebook , Twitter and Instagram .